Forget Moderna: This Biotech Juggernaut Is Rising Fast
A biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
During recessions, some index funds fare better than others. This intro highlights selection criteria and defensive positioning.
25,743 articlesA biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
Mortgage rates rose again this week as inflation fears and geopolitical tensions weighed on bonds. The latest Freddie...
Quantum dreams meet market drama as Rigetti and peers grab headlines. This guide breaks down why rigetti computing st...
A Philadelphia primary delivers a surprise win for a self-described 'proud troublemaker' democratic socialist, beatin...
Retail investors push Ford into meme-stock territory as Wall Street holds, sparking a heated debate about the automak...
A landmark, independent study finds racial disparities in AI-driven hiring tools used by major employers, affecting B...
Developers race to add native privacy to Ethereum as investors rotate into privacy-first assets. A 12-month deadline ...
JPMorgan argues a bold AI productivity push—the moonshot to avoid trillion national debt—could avert a looming $39 tr...
Palantir faces a steeper path in 2026 as the stock retreats, yet bulls argue the core AI platform and government dema...
Microsoft’s stock has drifted lower this year even as its AI and cloud businesses show stronger momentum. This piece ...
Bond yields climbed this week, increasing borrowing costs for homebuyers and businesses while influencing stock marke...
A software stock that doubled since April caught my eye for reasons beyond hype. In this guide, I explain the growth ...